Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.

Date publication

septembre 2021

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana , Dr DAGUINDAU Etienne

Tous les auteurs :
Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Le Gouill S, Béné MC, Chevallier P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34547182

Résumé

Three different scoring systems have been developed to assess pre-transplant comorbidity in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): the Hematopoietic Cell Transplantation-Specific Comorbidity Index, the Comorbidity/Age index, and the Augmented Comorbidity/Age index. All were devised to predict overall survival (OS) and disease-free survival (DFS) survivals and non-relapse mortality (NRM) in patients receiving HLA-matched Allo-HSCT, but their performance has scarcely been studied in the haploidentical Allo-HSCT setting with post-transplant cyclophosphamide, a procedure in constant expansion worldwide.

Mots clés

HSCT-CI, PTCY, allogeneic hematopoietic stem cell transplantation, augmented comorbidity/age index, comorbidity/age index, haploidentical

Référence

Cancer Med. 2021 Sep 21;: